Solid Tumors, Adult Clinical Trial
Official title:
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients With Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
After being informed about the study including potential risks, patients giving written informed consent will proceed to a screening period when assessments will be performed to determine whether the patient is eligible to participate in the study. If the patient is eligible, they will start to receive ON 123300 as capsules every day. On day 1 and Day 8 of the study, patients will be required to provide eight blood samples to allow measurement of the amount of drug in their blood. Three ECGs will also be performed during this time. Patients will continue to receive ON 123300 until disease progression, unacceptable toxicity, or patient or physician decision to stop. The first group of patients will receive 40mg of ON 123300 daily, the next group 80mg of ON 123300, the 120mg, etc. until the correct dose has been determined for future studies. Patients will visit the clinic on Days 1, 2, 8, and 9, then weekly for the first month, then every two weeks for two more months, then every month. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06404528 -
Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours
|
N/A | |
| Terminated |
NCT04467853 -
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT05698888 -
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04587479 -
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT05472220 -
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05354323 -
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05430373 -
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05747339 -
A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors
|
N/A | |
| Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05228015 -
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05018273 -
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04621435 -
Imaging of Solid Tumors Using FAP-2286
|
Phase 1 | |
| Recruiting |
NCT05861895 -
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06088472 -
TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
|
Early Phase 1 | |
| Recruiting |
NCT05768139 -
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 |